Trials & Tribulations Of adaptive and factorial designsA biostatistician’s interpretation of last week’s ODAC August 02, 2024Vol.50 No.31By Donald A. Berry
Trials & Tribulations Better oncology drug management could lead to improved outcomes, lower costs July 26, 2024Vol.50 No.30By Matt Ingram
NCI’s Virtual Clinical Trials Office fills the staffing shortages at cancer centers June 28, 2024Vol.50 No.26By Matthew Bin Han Ong
Trials & Tribulations The thorny road to drug approval for myelodysplastic syndromes June 14, 2024Vol.50 No.24By Mikkael A. Sekeres
Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC June 07, 2024Vol.50 No.23By Jacquelyn Cobb and McKenzie Prillaman
Trials & Tribulations Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists June 07, 2024Vol.50 No.23By Rebecca Sutphen
Trials & Tribulations Are we focused on the wrong risk type in genetic screening?Breast cancer screening study shows new paths to population screening May 24, 2024Vol.50 No.21By Cassie Hajek
HRD results can vary widely, depending on what assay you choose—even as they guide treatment choices May 17, 2024Vol.50 No.20By Jacquelyn Cobb
RWE study pinpoints gaps in mental health care utilization among parents of children with cancer May 17, 2024Vol.50 No.20By McKenzie Prillaman
Trials & Tribulations Single-cell based precision oncology: First steps in addressing and overcoming tumor heterogeneity May 10, 2024Vol.50 No.19By Sanju Sinha and Eytan Ruppin
